drugset / Trial / NCT02341456

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

NCT02341456

Phase 1 Completed 19 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.

Timeline

Start
2015-01-16
Primary completion
2016-12-14
Completion
2018-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Adavosertib Small molecule Oral
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications